View ValuationShenzhen Hepalink Pharmaceutical Group 将来の成長Future 基準チェック /36Shenzhen Hepalink Pharmaceutical Group利益と収益がそれぞれ年間53%と5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に5.8% 53.3%なると予測されています。主要情報53.0%収益成長率53.28%EPS成長率Pharmaceuticals 収益成長14.9%収益成長率5.0%将来の株主資本利益率5.76%アナリストカバレッジLow最終更新日16 Sep 2024今後の成長に関する最新情報お知らせ • Jan 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the year ended December 31, 2025. for the year, Net profit attributable to shareholders of the listed company of RMB 284.00 million to RMB 377.00 million . Basic earnings per share of RMB 0.1936 per share to RMB 0.2569 per share. reasons for changes in the results: During the Reporting Period, the Group achieved significant progress in expanding its global heparin finished dose business. Sales performance across all regions showed steady growth, with market share continuing to increase. Sales volume of enoxaparin finished dose achieved double-digit growth, further solidifying the Group's global competitive position. During the Reporting Period, the Company's net profit attributable to shareholders of the listed company decreased year-on-year. This was primarily due to a high base formed by non-recurring profit or loss from a one-time investment income exceeding RMB 350 million in the corresponding period of last year. Additionally, an associate company of the Company is expected to have a certain impact on the Group's net profit due to its research and development progress falling short of expectations. The specific impact is subject to final confirmation by the accounting firm. Net profit attributable to shareholders of the listed company (after non-recurring profit or loss) increased as compared with the corresponding period of last year during the Reporting Period, primarily driven by steady growth in core business revenue and profits. Concurrently, the Company continued to enhance operational efficiency and drive sustained profitability improvements through strengthened financial management and optimized resource allocation. Although the associate company is expected to have a certain impact on the Group's net profit (after non-recurring profit or loss), the Group still achieved steady growth in net profit (after non-recurring profit or loss), demonstrating its operational resilience and sustained growth capability of its core business.お知らせ • Jan 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the year ending December 31, 2022, the company expects net profit attributable to shareholders of the listed company of RMB 617.00 million to RMB 773.00 million, increase as compared with the corresponding period: 156.24% to 221.03% and basic earnings per share of RMB 0.4205 per share to RMB 0.5268 per share.すべての更新を表示Recent updatesお知らせ • Jun 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026お知らせ • Mar 31+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026お知らせ • Jan 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the year ended December 31, 2025. for the year, Net profit attributable to shareholders of the listed company of RMB 284.00 million to RMB 377.00 million . Basic earnings per share of RMB 0.1936 per share to RMB 0.2569 per share. reasons for changes in the results: During the Reporting Period, the Group achieved significant progress in expanding its global heparin finished dose business. Sales performance across all regions showed steady growth, with market share continuing to increase. Sales volume of enoxaparin finished dose achieved double-digit growth, further solidifying the Group's global competitive position. During the Reporting Period, the Company's net profit attributable to shareholders of the listed company decreased year-on-year. This was primarily due to a high base formed by non-recurring profit or loss from a one-time investment income exceeding RMB 350 million in the corresponding period of last year. Additionally, an associate company of the Company is expected to have a certain impact on the Group's net profit due to its research and development progress falling short of expectations. The specific impact is subject to final confirmation by the accounting firm. Net profit attributable to shareholders of the listed company (after non-recurring profit or loss) increased as compared with the corresponding period of last year during the Reporting Period, primarily driven by steady growth in core business revenue and profits. Concurrently, the Company continued to enhance operational efficiency and drive sustained profitability improvements through strengthened financial management and optimized resource allocation. Although the associate company is expected to have a certain impact on the Group's net profit (after non-recurring profit or loss), the Group still achieved steady growth in net profit (after non-recurring profit or loss), demonstrating its operational resilience and sustained growth capability of its core business.お知らせ • Dec 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Sep 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025お知らせ • Jul 18Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Completes the First Subject and the First Dosing in the Phase 1 Clinical TrialShenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that the Company has recently completed the enrollment of the first subject and the first dosing in the phase I clinical trial of its independently developed innovative candidate drug, the H1710 injection. In February 2025, the Company received the Notice of Approval for Clinical Trial issued by the National Medical Products Administration for approving the clinical trial of the H1710 injection. This clinical trial is an open-label, dose-escalation Phase Ia clinical study, evaluating the safety, tolerability and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. This is the first in-human trial for H1710, which is planned to be conducted at three research centers, with an estimated enrollment of about 36 patients. H1710 is an innovative drug targeting heparanase for the treatment of advanced solid tumors. To the best knowledge of the Company, as of the date of this announcement, there are no products with the same molecular mechanism that have been approved for marketing anywhere in the world.お知らせ • Jul 02Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025お知らせ • Mar 31+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025お知らせ • Mar 28+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2025.お知らせ • Feb 18Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration for Approving the H1710 InjectionShenzhen Hepalink Pharmaceutical Group Co., Ltd. board of directors announced that the Company has recently received the Notice of Approval for Clinical Trial issued by the National Medical Products Administration ("NMPA") for approving the H1710 injection ("H1710"). Relevant information is as follows. Drug Name: H1710 injection. Indications: Advanced solid tumor. Registration Classification: Class 1 chemical drug. Application Matter: Clinical trial. Applicant: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Review Conclusions: According to the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, the investigational new drug application for the H1710 injection accepted on December 3, 2024 meets the relevant requirements for drug registration, and this drug has been approved to conduct clinical trials as monotherapy for the treatment of advanced solid tumors H1710 is a candidate drug independently developed by the Company, and the Company owns the global rights to develop and commercialize H1710. H1710 is a novel compound that targets heparanase, a heparin-degrading enzyme. It has a suitable chain length and a unique flexible structure, and competitively binds to heparanase with heparan sulfate proteoglycans or heparin, making it a highly efficient and selective heparanase inhibitor. Heparanase is overexpressed in various tumors and is associated with tumor growth and metastasis. Studies have shown that targeting heparanase is a new anticancer strategy. The Company's preclinical research has demonstrated that H1710 exhibits anti-tumor pharmacological activity by inhibiting the activity and expression of heparanase. H1710 has shown significant anti-tumor effects in various tumor animal models. As at the date of this announcement, there is no similar product with the same molecular mechanism on the market worldwide. According to the relevant laws and regulations related to national drug registration, drugs are required to conduct clinical trials and obtain relevant data after receiving the Notice of Approval for Clinical Trial, and can only be marketed after being approved by the NMPA. Since clinical research involves a long cycle, high investment and many unpredictable factors during the process, there are many uncertainties regarding the results and time of clinical trials, review and approval. The Company will fulfill its information disclosure obligations in a timely manner for subsequent development progress. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.お知らせ • Dec 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025お知らせ • Sep 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024お知らせ • Jun 29Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024お知らせ • Mar 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024お知らせ • Dec 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Mar 29, 2024お知らせ • Aug 22Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Change of Financial Controller from Mr. Xiang Xianqing to Ms. Chen JuanShenzhen Hepalink Pharmaceutical Group Co., Ltd. announced change of financial controller from Mr. Xiang Xianqing to Ms. Chen Juan with effect from August 21, 2023. Ms. Chen, 48, is a seasoned financial manager with more than 20 years of financial management experience in large multinational companies. She obtained a bachelor's degree in economics from Hubei University and received a master's degree in accounting from Tsinghua University. She also holds a licence as a Chartered Global Management Accountant and is a member of Institute of Public Accountants. From 2012 to 2015, she served as the financial director of IBM System Technology (Shenzhen) Co., Ltd. and Lenovo System Technology (Shenzhen) Co., Ltd.; from 2016 to 2017, she served as the head of internal control of the hardware system maintenance division of IBM Greater China; from 2017 to 2022, she was the person-in-charge of SF Express Group customer settlement center; from 2022 to 2023, she was the financial controller of SF Airlines; she joined Hepalink in August 2023.お知らせ • Jul 12Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on July 18, 2023Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced final cash dividend of CNY 1.00 per 10 shares on A shares for the year 2022. Record date is July 17, 2023, Ex-Date is July 18, 2023 and Payment Date is July 18, 2023.お知らせ • May 26Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022Shenzhen Hepalink Pharmaceutical Group Co., Ltd. at its Annual General Meeting held on 22 May 2023 approved cash dividend of CNY 1.00000000 per 10 shares (tax included) for 2022.お知らせ • May 23+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Directorate ChangesShenzhen Hepalink Pharmaceutical Group Co., Ltd. announced Poll Results of the 2022 Annual General Meeting Held on May 22, 2023 and approved appointment of Mr. Huang Peng as an independent non-executive Director of the Company and appointment of Mr. Yi Ming as an independent non-executive Director of the Company.お知らせ • Jan 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the year ending December 31, 2022, the company expects net profit attributable to shareholders of the listed company of RMB 617.00 million to RMB 773.00 million, increase as compared with the corresponding period: 156.24% to 221.03% and basic earnings per share of RMB 0.4205 per share to RMB 0.5268 per share.業績と収益の成長予測OTCPK:SHEZ.F - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20266,173786N/AN/A112/31/20255,779728N/AN/A112/31/20245,343691N/AN/A16/30/20245,570-2431,8392,236N/A3/31/20245,518-6951,0441,493N/A12/31/20235,446-783-47398N/A9/30/20235,827218-606-271N/A6/30/20236,114340-1,314-1,059N/A3/31/20236,550559-1,212-969N/A1/1/20237,159727-979-757N/A9/30/20227,129432-1,060-849N/A6/30/20227,010414-722-513N/A3/31/20227,008332-611-428N/A1/1/20226,365241-200-7N/A9/30/20216,42177796290N/A6/30/20215,786781359548N/A3/31/20215,198912484675N/A12/31/20205,3321,024-17537N/A9/30/20205,0281,097-456-206N/A6/30/20205,1551,094-603-290N/A3/31/20205,004808-634-307N/A12/31/20194,6251,059-590-228N/A9/30/20194,622812-483-9N/A6/30/20194,736894-184304N/A3/31/20194,8791,03069575N/A12/31/20184,815591101636N/A9/30/20184,307565-5472N/A6/30/20183,905437-742-164N/A3/31/20183,347278N/A-500N/A12/31/20172,843197N/A-486N/A9/30/20172,486176N/A-404N/A6/30/20172,218140N/A50N/A3/31/20172,045189N/A226N/A12/31/20162,261397N/A346N/A9/30/20162,318466N/A436N/A6/30/20162,279566N/A603N/A3/31/20162,223590N/A694N/A12/31/20152,292580N/A894N/A9/30/20152,141532N/A936N/A6/30/20152,251503N/A1,128N/A3/31/20152,387453N/A1,029N/A12/31/20141,959338N/A913N/A9/30/20141,718250N/A726N/A6/30/20141,477177N/A475N/A3/31/20141,375249N/A513N/A12/31/20131,513317N/A421N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SHEZ.Fは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.5% ) よりも高い成長率であると考えられます。収益対市場: SHEZ.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: SHEZ.F今後 3 年以内に収益を上げることが予想されます。収益対市場: SHEZ.Fの収益 ( 5% ) US市場 ( 12.4% ) よりも低い成長が予測されています。高い収益成長: SHEZ.Fの収益 ( 5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SHEZ.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 5.8 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/11 08:28終値2024/07/15 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Ziyi ChenGoldman SachsYinglan ShuHaitong International Research LimitedLaurence TamMorgan Stanley1 その他のアナリストを表示
お知らせ • Jan 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the year ended December 31, 2025. for the year, Net profit attributable to shareholders of the listed company of RMB 284.00 million to RMB 377.00 million . Basic earnings per share of RMB 0.1936 per share to RMB 0.2569 per share. reasons for changes in the results: During the Reporting Period, the Group achieved significant progress in expanding its global heparin finished dose business. Sales performance across all regions showed steady growth, with market share continuing to increase. Sales volume of enoxaparin finished dose achieved double-digit growth, further solidifying the Group's global competitive position. During the Reporting Period, the Company's net profit attributable to shareholders of the listed company decreased year-on-year. This was primarily due to a high base formed by non-recurring profit or loss from a one-time investment income exceeding RMB 350 million in the corresponding period of last year. Additionally, an associate company of the Company is expected to have a certain impact on the Group's net profit due to its research and development progress falling short of expectations. The specific impact is subject to final confirmation by the accounting firm. Net profit attributable to shareholders of the listed company (after non-recurring profit or loss) increased as compared with the corresponding period of last year during the Reporting Period, primarily driven by steady growth in core business revenue and profits. Concurrently, the Company continued to enhance operational efficiency and drive sustained profitability improvements through strengthened financial management and optimized resource allocation. Although the associate company is expected to have a certain impact on the Group's net profit (after non-recurring profit or loss), the Group still achieved steady growth in net profit (after non-recurring profit or loss), demonstrating its operational resilience and sustained growth capability of its core business.
お知らせ • Jan 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the year ending December 31, 2022, the company expects net profit attributable to shareholders of the listed company of RMB 617.00 million to RMB 773.00 million, increase as compared with the corresponding period: 156.24% to 221.03% and basic earnings per share of RMB 0.4205 per share to RMB 0.5268 per share.
お知らせ • Jun 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026
お知らせ • Mar 31+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
お知らせ • Jan 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the year ended December 31, 2025. for the year, Net profit attributable to shareholders of the listed company of RMB 284.00 million to RMB 377.00 million . Basic earnings per share of RMB 0.1936 per share to RMB 0.2569 per share. reasons for changes in the results: During the Reporting Period, the Group achieved significant progress in expanding its global heparin finished dose business. Sales performance across all regions showed steady growth, with market share continuing to increase. Sales volume of enoxaparin finished dose achieved double-digit growth, further solidifying the Group's global competitive position. During the Reporting Period, the Company's net profit attributable to shareholders of the listed company decreased year-on-year. This was primarily due to a high base formed by non-recurring profit or loss from a one-time investment income exceeding RMB 350 million in the corresponding period of last year. Additionally, an associate company of the Company is expected to have a certain impact on the Group's net profit due to its research and development progress falling short of expectations. The specific impact is subject to final confirmation by the accounting firm. Net profit attributable to shareholders of the listed company (after non-recurring profit or loss) increased as compared with the corresponding period of last year during the Reporting Period, primarily driven by steady growth in core business revenue and profits. Concurrently, the Company continued to enhance operational efficiency and drive sustained profitability improvements through strengthened financial management and optimized resource allocation. Although the associate company is expected to have a certain impact on the Group's net profit (after non-recurring profit or loss), the Group still achieved steady growth in net profit (after non-recurring profit or loss), demonstrating its operational resilience and sustained growth capability of its core business.
お知らせ • Dec 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Sep 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025
お知らせ • Jul 18Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Completes the First Subject and the First Dosing in the Phase 1 Clinical TrialShenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that the Company has recently completed the enrollment of the first subject and the first dosing in the phase I clinical trial of its independently developed innovative candidate drug, the H1710 injection. In February 2025, the Company received the Notice of Approval for Clinical Trial issued by the National Medical Products Administration for approving the clinical trial of the H1710 injection. This clinical trial is an open-label, dose-escalation Phase Ia clinical study, evaluating the safety, tolerability and preliminary anti-tumor activity of H1710 in patients with advanced solid tumors. This is the first in-human trial for H1710, which is planned to be conducted at three research centers, with an estimated enrollment of about 36 patients. H1710 is an innovative drug targeting heparanase for the treatment of advanced solid tumors. To the best knowledge of the Company, as of the date of this announcement, there are no products with the same molecular mechanism that have been approved for marketing anywhere in the world.
お知らせ • Jul 02Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025
お知らせ • Mar 31+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
お知らせ • Mar 28+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Annual General Meeting, May 22, 2025.
お知らせ • Feb 18Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration for Approving the H1710 InjectionShenzhen Hepalink Pharmaceutical Group Co., Ltd. board of directors announced that the Company has recently received the Notice of Approval for Clinical Trial issued by the National Medical Products Administration ("NMPA") for approving the H1710 injection ("H1710"). Relevant information is as follows. Drug Name: H1710 injection. Indications: Advanced solid tumor. Registration Classification: Class 1 chemical drug. Application Matter: Clinical trial. Applicant: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Review Conclusions: According to the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, the investigational new drug application for the H1710 injection accepted on December 3, 2024 meets the relevant requirements for drug registration, and this drug has been approved to conduct clinical trials as monotherapy for the treatment of advanced solid tumors H1710 is a candidate drug independently developed by the Company, and the Company owns the global rights to develop and commercialize H1710. H1710 is a novel compound that targets heparanase, a heparin-degrading enzyme. It has a suitable chain length and a unique flexible structure, and competitively binds to heparanase with heparan sulfate proteoglycans or heparin, making it a highly efficient and selective heparanase inhibitor. Heparanase is overexpressed in various tumors and is associated with tumor growth and metastasis. Studies have shown that targeting heparanase is a new anticancer strategy. The Company's preclinical research has demonstrated that H1710 exhibits anti-tumor pharmacological activity by inhibiting the activity and expression of heparanase. H1710 has shown significant anti-tumor effects in various tumor animal models. As at the date of this announcement, there is no similar product with the same molecular mechanism on the market worldwide. According to the relevant laws and regulations related to national drug registration, drugs are required to conduct clinical trials and obtain relevant data after receiving the Notice of Approval for Clinical Trial, and can only be marketed after being approved by the NMPA. Since clinical research involves a long cycle, high investment and many unpredictable factors during the process, there are many uncertainties regarding the results and time of clinical trials, review and approval. The Company will fulfill its information disclosure obligations in a timely manner for subsequent development progress. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.
お知らせ • Dec 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025
お知らせ • Sep 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024
お知らせ • Jun 29Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024
お知らせ • Mar 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024
お知らせ • Dec 30Shenzhen Hepalink Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Mar 29, 2024
お知らせ • Aug 22Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Change of Financial Controller from Mr. Xiang Xianqing to Ms. Chen JuanShenzhen Hepalink Pharmaceutical Group Co., Ltd. announced change of financial controller from Mr. Xiang Xianqing to Ms. Chen Juan with effect from August 21, 2023. Ms. Chen, 48, is a seasoned financial manager with more than 20 years of financial management experience in large multinational companies. She obtained a bachelor's degree in economics from Hubei University and received a master's degree in accounting from Tsinghua University. She also holds a licence as a Chartered Global Management Accountant and is a member of Institute of Public Accountants. From 2012 to 2015, she served as the financial director of IBM System Technology (Shenzhen) Co., Ltd. and Lenovo System Technology (Shenzhen) Co., Ltd.; from 2016 to 2017, she served as the head of internal control of the hardware system maintenance division of IBM Greater China; from 2017 to 2022, she was the person-in-charge of SF Express Group customer settlement center; from 2022 to 2023, she was the financial controller of SF Airlines; she joined Hepalink in August 2023.
お知らせ • Jul 12Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on July 18, 2023Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced final cash dividend of CNY 1.00 per 10 shares on A shares for the year 2022. Record date is July 17, 2023, Ex-Date is July 18, 2023 and Payment Date is July 18, 2023.
お知らせ • May 26Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022Shenzhen Hepalink Pharmaceutical Group Co., Ltd. at its Annual General Meeting held on 22 May 2023 approved cash dividend of CNY 1.00000000 per 10 shares (tax included) for 2022.
お知らせ • May 23+ 1 more updateShenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Directorate ChangesShenzhen Hepalink Pharmaceutical Group Co., Ltd. announced Poll Results of the 2022 Annual General Meeting Held on May 22, 2023 and approved appointment of Mr. Huang Peng as an independent non-executive Director of the Company and appointment of Mr. Yi Ming as an independent non-executive Director of the Company.
お知らせ • Jan 31Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the year ending December 31, 2022, the company expects net profit attributable to shareholders of the listed company of RMB 617.00 million to RMB 773.00 million, increase as compared with the corresponding period: 156.24% to 221.03% and basic earnings per share of RMB 0.4205 per share to RMB 0.5268 per share.